Nanocomplexes from RGD-modified generation 1.0 polyamidoamine based copolymers used for intravascular gene release to prevent restenosis. (February 2016)

• Record Type: Journal Article
• Authors: Cao, Duanwen; Tian, Shouqin; Yi, Wu; Dai, Gang; Chen, Jianhai; Feng, Min; Pan, Shirong
• Is Part Of: Nanomedicine. Volume 11:Number 4(2016)
• Page Start: 359
• Page End: 375
• Publication Date: 2016-02
• Subjects: human umbilical vein endothelial cells -- intravascular specific site release -- nanocomplexes -- PAMAM G1 -- patency -- pVEGF165 gene -- restenosis -- RGD peptide -- targeting -- transfection efficiency; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.15.201
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To validate the efficacy of nanocomplexes from RGD-modified polyamidoamine (PAMAM G1) copolymer for prevention of restenosis.Materials & methods: Generation 1.0 polyamidoamine (PAMAM G1)-based copolymers (PGP) and RGD modified PGP (PGP-RGD) were synthesized and its properties were evaluated. Intravascular VEGF165 release tests were performed.Results: The PGP-RGD1 (2.6% grafting rate) exhibited lower cytotoxicity and larger combining ability with pDNA. The complexes had sizes of 80–160 nm and zeta potentials of 3–20 mV. Transfection efficiency of PGP-RGD1 complexes in human umbilical vein endothelial cells was larger than that of PGP complexes. Patency and expression level of artery in PGP-RGD1 group were higher than that in saline group.Conclusion: PGP-RGD1 will be a promising targeted gene vector.